SCHEMBL3371956

SCHEMBL3371956

COC(=O)C1CC(O)CN1C(=O)C(NC(=O)OC(C)(C)C)C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ELANE P08246 13/20 0.44
ALDH1A1 P00352 1/20 0.43
VHL P40337 3/20 0.42
ELOC Q15369 2/20 0.42
ELOB Q15370 2/20 0.42
MMP2 P08253 1/20 0.41
ANPEP P15144 1/20 0.41
PEPD P12955 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10292790 1.00 ELANE (0.44) ELANEALDH1A1VHLELOCELOB
SCHEMBL806128 1.00 ELANE (0.44) ELANEALDH1A1VHLELOCELOB
SCHEMBL13318866 1.00 ELANE (0.44) ELANEALDH1A1VHLELOCELOB
SCHEMBL20120875 1.00 ELANE (0.44) ELANEALDH1A1VHLELOCELOB
SCHEMBL8015855 1.00 ELANE (0.44) ELANEALDH1A1VHLELOCELOB
SCHEMBL20120873 1.00 ELANE (0.44) ELANEALDH1A1VHLELOCELOB
SCHEMBL8253158 1.00 ELANE (0.44) ELANEALDH1A1VHLELOCELOB
SCHEMBL10347003 0.90 PEPD (0.47) ELANEVHLELOCELOBMMP2
SCHEMBL13744721 0.90 PEPD (0.47) ELANEVHLELOCELOBMMP2
SCHEMBL13817413 0.89 ANPEP (0.56) ELANEVHLELOCELOBMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809267-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2014-08-19 US disclosed
US-20140051626-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-02-20 US disclosed
US-8513186-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-08-20 US disclosed
EP-2162432-A2 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2010-03-17 EP disclosed
US-20090304631-A1 HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR PHENOMIX CORPORATION 2009-12-10 US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
EP-2029153-A2 HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR Phenomix Corporation (US) 2009-03-04 EP disclosed
WO-2009005677-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-01-08 WO disclosed
WO-2007089618-A2 HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR PHENOMIX CORPORATION (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186869-A1 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 ELANE 1237/4885ALDH1A1 3957/4885VHL 1251/4885
US-20090304631-A1 HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR PREP, CTSC, PEPD ELANE 208/4885ALDH1A1 2163/4885VHL 939/4885
US-20140051626-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ELANE 1237/4885ALDH1A1 3957/4885VHL 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.